1. Palmitic acid induces down-regulation of APOM expression, is mediated via the PPARβ/δ pathway.
2. Palmitic acid induces anxiety-like behavior in mice while increasing amygdala-based serotonin metabolism.
3. Dietary TAGs with an increased proportion of Palmitic acid in the sn-2 position do not have acute adverse effects on the insulin and glucose response to meals in healthy men and women, but they decrease GIP release.
4. Palmitic acid has a significant impact on proliferation and differentiation of NSCs in vitro and may be useful for elucidating the role of SFAs in regulating NSCs fate in physiological and pathological settings.
1. Bavachinin could be used as a therapeutic agent for inhibiting tumor angiogenesis.
2. Bavachinin can inhibit tube formation in human umbilical vein endothelial cells (HUVECs) as well as in vitro migration of KB cells.
3. Bavachinin decreases transcription of genes associated with angiogenesis and energy metabolism that are regulated by HIF-1, such as vascular endothelial growth factors (VEGF), Glut 1 and Hexokinase.
4. Bavachinin inhibits increases in HIF-1α activity in human KB carcinoma (HeLa cell derivative) and human HOS osteosarcoma cells under hypoxia in a concentration-dependent manner, probably by enhancing the interaction between von Hippel-Lindau (VHL) and HIF-1α.
1. Timosaponin A3 triggers liver injury through inducing ROS generation and suppressing the expression of BA transporters.
2. Mangiferin, an active component in Anemarrhena, may protect hepatocytes from Timosaponin A3-induced hepatotoxicity.
1. Brazilin exhibits anti-hepatotoxic, antiplatelet effects.
2. Brazilin has cancer preventive effect, may inhibit T24 cell growth and trigger cell death through a c-Fos-mediated and tumor cell specific signaling pathway.
3. Brazilin has anti-inflammatory property, can suppress mastitis and high glucose-induced vascular inflammatory process related with the inhibition of oxidative stress, CAMs expression, and NF-κB activation in HUVEC; may be useful to treat chronic inflammatory disorders including rheumatoid arthritis.
1. Seneciphylline can significantly increased the activities of epoxide hydrase and glutathione-S-transferase but cause reduction of cytochrome P-450 and related monooxygenase activities.
2. Seneciphylline and senecionine can not produce any prominent in vitro effect on the hepatic drug metabolizing enzymes under study, but senecionine slight stimulate alkaloids and slight reduction of aminopyrine demethylase activity .